The risk for acute kidney injury was not higher among patients with an eGFR dip at empagliflozin initiation. Previous studies have reported renal benefits with sodium glucose cotransporter 2 inhibitor ...
Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung ca ...
Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...
A new BLA for Dato-DXd targets EGFR-mutated NSCLC, following withdrawal of a previous application based on TROPION-Lung01 trial data. The new submission is supported by phase 2 TROPION-Lung05 trial ...
Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience. Prognostic nomogram for overall survival in patients with stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback